Classes
DEA Class; Rx
Common Brand Names; Technivie
- NS3/4A Protease Inhibitor Antivirals in Combination with NS5A Protein Inhibitor Antivirals for Hepatitis C
Description
3 drug oral combination product including a HCV NS5A inhibitor, a NS3/4A protease inhibitor, and a pharmacokinetic enhancer
For use with ribavirin in the treatment of genotype 4 hepatitis C virus (HCV) infections in patients without cirrhosis or with compensated cirrhosis
Contraindicated in patients with moderate to severe hepatic disease
Indications
Indicated for the treatment of genotype 4 chronic hepatitis C infection in patients without cirrhosis or with compensated cirrhosis.
Contraindications
Ombitasvir; paritaprevir; ritonavir is recommended for use with ribavirin; therefore, any contraindication to ribavirin will also apply to the combination regimen
Adverse Effects
suicidal ideation
atrial fibrillation
erythema multiforme
angioedema reactions or anaphylaxis
hepatic failure
hepatitis B exacerbation
Pregnancy and Lactation
According to the manufacturer, it is not known if ombitasvir; paritaprevir; ritonavir or their metabolites are excreted in human milk.
Maximum Dosage
90 mg/day PO for ledipasvir; 400 mg/day PO for sofosbuvir.
90 mg/day PO for ledipasvir; 400 mg/day PO for sofosbuvir.
weighing 35 kg or more: 90 mg/day PO for ledipasvir; 400 mg/day PO for sofosbuvir.
weighing 17 to 34 kg: 45 mg/day PO for ledipasvir; 200 mg/day PO for sofosbuvir.
3 to 12 years weighing 35 kg or more: 90 mg/day PO for ledipasvir; 400 mg/day PO for sofosbuvir.
3 to 12 years weighing 17 to 34 kg: 45 mg/day PO for ledipasvir; 200 mg/day PO for sofosbuvir.
3 to 12 years weighing less than 17 kg: 33.75 mg/day PO for ledipasvir; 150 mg/day PO for sofosbuvir.
1 to 2 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Ombitasvir/paritaprevir/ritonavir
Technivie Oral Tab: 12.5-75-50mg
